Prognostic microRNAs as biomarkers for prostate cancer.
| Autor: | Palanisamy H; Department of Biotechnology, PSG College of Technology, Coimbatore Tamil Nadu, India., Manoharan JP, Vidyalakshmi S |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of cancer research and therapeutics [J Cancer Res Ther] 2024 Jan 01; Vol. 20 (1), pp. 297-303. Date of Electronic Publication: 2023 Apr 06. |
| DOI: | 10.4103/jcrt.jcrt_1469_22 |
| Abstrakt: | Objective: Prostate cancer is the second largest cancer, most commonly diagnosed in men. Several studies reveal that miRNAs (microRNAs) are involved in various stages of prostate cancer. miRNAs are a family of small non-coding RNA species that have been implicated in the post-transcriptional regulation of gene expression. The present in silico study aims at identifying miRNA biomarkers that are significantly associated with the regulation of genes involved in prostate cancer. Methods: Dataset of miRNA and mRNA of prostate adenocarcinoma patients and controls was downloaded from The Cancer Genome Atlas (TCGA), and differential gene expression analysis was carried out. ROC and Kaplan-Meier survival analyses were performed on differentially expressed miRNAs. Pathway analysis was carried out for significant miRNAs, and protein-protein interaction of involved genes and miRNAs was examined. Results: A total of 185 miRNAs were differentially expressed between the patients and the control. ROC and Kaplan-Meier survival analysis showed that the two miRNAs hsa-mir-133b and hsa-mir-17-5p were found to be significantly associated with prostate cancer prognosis. HAS2 and EPHA10 gene targets of identified miRNA were also differentially expressed. A protein-protein interaction (PPI) network was constructed, and the HAS2 gene was found to be interacting with the epidermal growth factor receptor (EGFR). Conclusion: This study highlights the potential of hsa-mir-133b and hsa-mir-17-5p miRNAs as biomarkers for the prognosis of prostate cancer. However, further experimental studies are required to validate this finding. (Copyright © 2023 Copyright: © 2023 Journal of Cancer Research and Therapeutics.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|